{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06252649",
            "orgStudyIdInfo": {
                "id": "20210081"
            },
            "organization": {
                "fullName": "Amgen",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-na\u00efve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation",
            "officialTitle": "Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-na\u00efve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)",
            "acronym": "CodeBreaK 301"
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Amgen",
                "class": "INDUSTRY"
            }
        },
        "descriptionModule": {
            "briefSummary": "The aim of this study is to compare progression free survival (PFS) in treatment-na\u00efve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Colorectal Cancer"
            ],
            "keywords": [
                "Sotorasib",
                "Panitumumab",
                "FOLFIRI",
                "Bevacizumab-awwb",
                "Oncology"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 450,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A: Sotorasib + Panitumumab + FOLFIRI",
                    "type": "EXPERIMENTAL",
                    "description": "Sotorasib was taken daily (QD) as an oral tablet. Panitumumab and FOLFIRI were received every 2 weeks (Q2W) via intravenous infusion (IV).",
                    "interventionNames": [
                        "Drug: FOLFIRI Regimen",
                        "Drug: Sotorasib",
                        "Drug: Panitumumab"
                    ]
                },
                {
                    "label": "Arm B: FOLFIRI with or Without Bevacizumab-awwb",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants received FOLFIRI Q2W with or without bevacizumab-awwb.",
                    "interventionNames": [
                        "Drug: FOLFIRI Regimen",
                        "Drug: Bevacizumab-awwb"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "FOLFIRI Regimen",
                    "description": "Combination of irinotecan, leucovorin, and 5-fluorouracil given intravenously Q2W.",
                    "armGroupLabels": [
                        "Arm A: Sotorasib + Panitumumab + FOLFIRI",
                        "Arm B: FOLFIRI with or Without Bevacizumab-awwb"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Sotorasib",
                    "description": "Immediate-release solid dosage form administered PO.",
                    "armGroupLabels": [
                        "Arm A: Sotorasib + Panitumumab + FOLFIRI"
                    ],
                    "otherNames": [
                        "AMG 510",
                        "Lumakras",
                        "Lumykras"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Panitumumab",
                    "description": "Administered IV Q2W.",
                    "armGroupLabels": [
                        "Arm A: Sotorasib + Panitumumab + FOLFIRI"
                    ],
                    "otherNames": [
                        "Vectibix"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bevacizumab-awwb",
                    "description": "Administered IV Q2W.",
                    "armGroupLabels": [
                        "Arm B: FOLFIRI with or Without Bevacizumab-awwb"
                    ],
                    "otherNames": [
                        "MVASI"
                    ]
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.\n* Central confirmation of KRAS p.G12C mutation\n* Measurable metastatic disease per RECIST v1.1 criteria.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of \u2264 1.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Active, untreated brain metastases.\n* Leptomeningeal disease\n* Previous treatment with a KRAS p.G12C inhibitor\n* History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amgen Call Center",
                    "role": "CONTACT",
                    "phone": "866-572-6436",
                    "email": "medinfo@amgen.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "MD",
                    "affiliation": "Amgen",
                    "role": "STUDY_DIRECTOR"
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "AmgenTrials clinical trials website",
                    "url": "http://www.amgentrials.com"
                }
            ]
        }
    },
    "hasResults": false
}